Elevated miR-222-3p promotes proliferation and invasion of endometrial carcinoma via targeting ERα

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Liu, Binya ^a   Che, Qi ^a   Qiu, Haifeng ^a   Bao, Wei ^a   Chen, Xiaoyue ^b   Lu, Wen ^b   Li, Bilan ^b   Wan, Xiaoping ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; MICRORNA 222; MIR 222-3P; RALOXIFENE; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOMA CELL LINE; CELL ACTIVITY; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CARCINOMA; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC CORRELATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR GROWTH; TUMOR INVASION; TUMOR XENOGRAFT;

ADULT; ANIMALS; CELL LINE, TUMOR; ENDOMETRIAL NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; RNA, NEOPLASM; S PHASE;

EID: 84900310912     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087563     Document Type: Article

References (43)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
2. Azueta A, Gatius S, Matias-Guiu X (2010) Endometrioid carcinoma of the endometrium: pathologic and molecular features. Semin Diagn Pathol 27: 226-240.
3. Wong YF, Cheung TH, Lo KW, Yim SF, Siu NS, et al. (2007) Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling. Oncogene 26: 1971-1982. (Pubitemid 46474633)
4. Zhang Y, Liu Z, Yu X, Zhang X, Lu S, et al. (2010) The association between metabolic abnormality and endometrial cancer: a large case-control study in China. Gynecol Oncol 117: 41-46.
5. Dedes KJ, Wetterskog D, Ashworth A, Kaye SB, Reis-Filho JS (2011) Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 8: 261-271.
6. Liang J, Shang Y (2013) Estrogen and cancer. Annu Rev Physiol 75: 225-240.
7. Rudolf Kaaks AL, Kurzer MS (2002) Obesity, Endogenous Hormones, and Endometrial Cancer Risk:A Synthetic Review. Cancer Epidemiol Biomarkers Prev 11: 1531-1543.
8. Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15: 10-17.
9. Salvesen HB, Haldorsen IS, Trovik J (2012) Markers for individualised therapy in endometrial carcinoma. The Lancet Oncology 13: e353-e361.
10. Engelsen IB, Stefansson IM, Akslen LA, Salvesen HB (2008) GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. Am J Obstet Gynecol 199: 543 e541-547.
11. Jongen V, Briet J, de Jong R, ten Hoor K, Boezen M, et al. (2009) Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol 112: 537-542.
12. Srijaipracharoen S, Tangjitgamol S, Tanvanich S, Manusirivithaya S, Khunnarong J, et al. (2010) Expression of ER, PR, and Her-2/neu in endometrial cancer: a clinicopathological study. Asian Pac J Cancer Prev 11: 215-220.
13. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
14. Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449: 682-688. (Pubitemid 47552092)
15. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, et al. (2005) A microRNA polycistron as a potential human oncogene. Nature 435: 828-833. (Pubitemid 40839734)
16. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, et al. (2005) A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353: 1793-1801. (Pubitemid 41549891)
17. Zhao JJ, Lin J, Yang H, Kong W, He L, et al. (2008) MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 283: 31079-31086.
18. Di Leva G, Gasparini P, Piovan C, Ngankeu A, Garofalo M, et al. (2010) MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst 102: 706-721.
19. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, et al. (2009) miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16: 498-509.
20. Sun K, Wang W, Zeng JJ, Wu CT, Lei ST, et al. (2011) MicroRNA-221 inhibits CDKN1C/p57 expression in human colorectal carcinoma. Acta Pharmacol Sin 32: 375-384.
21. Felicetti F, Errico MC, Bottero L, Segnalini P, Stoppacciaro A, et al. (2008) The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 68: 2745-2754. (Pubitemid 351556272)
22. Creasman W (2009) Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet 105: 109.
23. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
24. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, et al. (2005) Endometrial cancer. The Lancet 366: 491-505. (Pubitemid 41111699)
25. Bray F, Loos AH, Oostindier M, Weiderpass E (2005) Geographic and temporal variations in cancer of the corpus uteri: incidence and mortality in pre- and postmenopausal women in Europe. Int J Cancer 117: 123-131. (Pubitemid 41262766)
26. Shang Y (2006) Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat Rev Cancer 6: 360-368.
27. Tan DS, Lambros MB, Marchio C, Reis-Filho JS (2008) ESR1 amplification in endometrial carcinomas: hope or hyperbole? J Pathol 216: 271-274.
28. Li M, Li J, Ding X, He M, Cheng SY (2010) microRNA and cancer. AAPS J 12: 309-317.
29. Leivonen SK, Makela R, Ostling P, Kohonen P, Haapa-Paananen S, et al. (2009) Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene 28: 3926-3936.
30. Zhao Y, Deng C, Wang J, Xiao J, Gatalica Z, et al. (2011) Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer. Breast Cancer Res Treat 127: 69-80.
31. Xiong J, Yu D, Wei N, Fu H, Cai T, et al. (2010) An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples. FEBS J 277: 1684-1694.
32. Pandey DP, Picard D (2009) miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA. Mol Cell Biol 29: 3783-3790.
33. Zhang C, Zhang J, Hao J, Shi Z, Wang Y, et al. (2012) High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma. J Transl Med 10: 119.
34. Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, et al. (2011) TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Sci Signal 4: ra41.
35. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, et al. (2007) miR- 221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 282: 23716-23724. (Pubitemid 47311902)
36. Cinti C, Vindigni C, Zamparelli A, La Sala D, Epistolato MC, et al. (2008) Activated Akt as an indicator of prognosis in gastric cancer. Virchows Arch 453: 449-455.
37. Pappas G, Zumstein LA, Munshi A, Hobbs M, Meyn RE (2007) Adenoviral-mediated PTEN expression radiosensitizes non-small cell lung cancer cells by suppressing DNA repair capacity. Cancer Gene Ther 14: 543-549. (Pubitemid 46788333)
38. Zhou S, Shen D, Wang Y, Gong L, Tang X, et al. (2012) microRNA-222 targeting PTEN promotes neurite outgrowth from adult dorsal root ganglion neurons following sciatic nerve transection. PLoS One 7: e44768.
39. Aglund K, Rauvala M, Puistola U, Angstrom T, Turpeenniemi-Hujanen T, et al. (2004) Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage. Gynecol Oncol 94: 699-704. (Pubitemid 39194463)
40. Talvensaari-Mattila A, Santala M, Soini Y, Turpeenniemi-Hujanen T (2005) Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma. Anticancer Res 25: 4101-4105. (Pubitemid 41665191)
41. Bollig A, Miksicek RJ (2000) An estrogen receptor-alpha splicing variant mediates both positive and negative effects on gene transcription. Mol Endocrinol 14: 634-649. (Pubitemid 32260508)
42. Giacinti L, Claudio PP, Lopez M, Giordano A (2006) Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 11: 1-8. (Pubitemid 43152681)
43. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, et al. (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281: 2189-2197. (Pubitemid 29275701)